Comparing Two Training Methods for Opioid Wizard
Study Details
Study Description
Brief Summary
The prevalence of opioid use disorder (OUD) and opioid-related deaths has risen dramatically in recent years. Effective treatments, including medications for opioid use disorder (MOUDs; e.g., buprenorphine-naloxone and methadone) are under-utilized. There are few evidence-based interventions for changing attitudes toward Opioid Use Disorder (OUD) in the general public and especially among healthcare clinicians. This study proposes an innovative intervention to change attitudes of Primary Care Clinicians (PCCs) toward persons with OUD. Study participants will be stratified into one of two online learning courses: the intervention training will be compared with an attention-control training.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Primary care offers an ideal setting in which to treat OUD; however, few clinicians are waivered to prescribe buprenorphine and of those who are waivered, less than one-third do prescribe. One potential barrier to increasing access to MOUDs are primary care clinician (PCC) attitudes towards people with OUD. This study will use a randomized controlled trial design to examine a novel intervention to change attitudes towards people with OUD among PCCs. PCCs in clinics randomized in COMPUTE 2.0 to the intervention (in 15 of the 30 clinics randomized in the parent study) will be randomized 1:1 to the intervention or comparison training, stratified by clinic and waiver status. Training will be conducted via MyLearning, an online learning software. PCCs will be asked to complete a brief training on the clinical decision support (CDS) tool, Opioid Wizard. PCCs in the intervention arm will hear patient narratives designed to shift attitudes about patients with OUD. PCCs in the comparison training will have training on using the clinical decision support tool. Immediately following the training, the PCCs will complete a survey of attitudes and intentions to get waivered to prescribe buprenorphine. Use of the CDS will be monitored in both groups for 6 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention PCCs in clinics randomized to Opioid Wizard will be randomized 1:1 to the intervention or comparison training, stratified by clinic and waiver status. Both arms will receive a case-based training on how to use the Opioid Wizard tool. The intervention arm will receive an online training that includes patient narratives and videos and person-first language. |
Behavioral: Online training
This intervention consists of two different interactive online trainings that are delivered through an online learning platform at HealthPartners.
|
| Placebo Comparator: Comparison training PCCs in clinics randomized to Opioid Wizard will be randomized 1:1 to the intervention or comparison training, stratified by clinic and waiver status. Both arms will receive a case-based training on how to use the Opioid Wizard tool. |
Behavioral: Online training
This intervention consists of two different interactive online trainings that are delivered through an online learning platform at HealthPartners.
|
Outcome Measures
Primary Outcome Measures
- OUD Attitudes [Immediately after completing online training and three-month follow-up.]
Attitudes toward people with OUD will be measured using the Difference and Disdain scales, which measure attitudes toward people with mental illness and substance use disorders (SUDs).
Secondary Outcome Measures
- Intentions to get waivered to prescribe buprenorphine. [Immediately after completing online training and three-month follow-up.]
Non-waivered PCCs will be asked to rate one question on their intentions to get waivered to prescribe buprenorphine.
- Intentions to prescribe buprenorphine should a waiver no longer be required. [Immediately after completing online training and three-month follow-up.]
Non-waivered PCCs will be asked to rate one question on their intentions to prescribe buprenorphine.
- Opioid Wizard Use [Six months following online training.]
The use rates for each PCC for the follow-up period (6 months) will be calculated as the proportion of eligible visits in which Opioid Wizard was used.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Primary Care Clinician: Must be a family physician, general internist, adult-care non-obstetric nurse practitioner, or a physician assistant
-
Must practice at a study-eligible primary care clinic already involved in the main study intervention arm
Exclusion Criteria:
None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | HealthPartners | Bloomington | Minnesota | United States | 55425-4516 |
Sponsors and Collaborators
- HealthPartners Institute
- Hennepin Healthcare Research Institute
- National Institute on Drug Abuse (NIDA)
Investigators
- Principal Investigator: Stephanie Hooker, PhD, HealthPartners Institute
Study Documents (Full-Text)
More Information
Publications
None provided.- A20-156
- 3UG1DA040316-06S4